New Triple-Drug cocktail targets tough leukemia mutations
NCT ID NCT04140487
First seen Oct 31, 2025 · Last updated May 15, 2026 · Updated 24 times
Summary
This study is for people with certain blood cancers (acute myeloid leukemia, chronic myelomonocytic leukemia, or high-risk myelodysplastic syndrome) that have a specific genetic change called a FLT3 mutation. The cancer has either come back or not responded to prior treatment. The trial tests a combination of three drugs: azacitidine (a chemotherapy), venetoclax (which blocks a protein that helps cancer cells survive), and gilteritinib (which targets the FLT3 mutation). The goal is to find the safest dose of gilteritinib and see if the three drugs together work better than standard treatments. About 97 adults will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.